Search
There is uncertainty if adding cryopercipitate empirically to all mass hemorrhage protocols has any benefit to mortality, need for transfusion, or any other meaningful outcome. This small study suggests it does not and that we should save the addition of cryopercipitate to those with lab proven low fibrinogen levels.
References
Empiric Cryoprecipitate Transfusion in Patients with Severe Hemorrhage: Results from the US Experience in the International CRYOSTAT-2 Trial
Van Gent, Jan-Michael DO, FACS; Kaminski, Carter W DO; Praestholm, Caroline BS; Pivalizza, Evan G MD; Clements, Thomas W MD; Kao, Lillian S MD, MS, FACS; Stanworth, Simon MD; Brohi, Karim MD; Cotton, Bryan A MD, MPH, FACS
Journal of the American College of Surgeons 238(4):p 636-643, April 2024. | DOI: 10.1097/XCS.0000000000000938